Matthews International Capital Management LLC Terns Pharmaceuticals, Inc. Transaction History

Matthews International Capital Management LLC

$589 Million
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 02, 2022	SELL	$5.65 - $10.73 $4.94 Million - $9.39 Million	-875,068 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$7.22 - $13.46 $1.42 Million - $2.64 Million	-196,353 Reduced 18.33%	875,068 $9.12 Million
Q1 2021 May 06, 2021	BUY	$17.13 - $27.25 $18.4 Million - $29.2 Million	1,071,421 New	1,071,421 $23.6 Million

Others Institutions Holding TERN

# of Institutions

167

Shares Held

78.3M

Call Options Held

580K

Put Options Held

454K

Orbimed Advisors LLC San Diego, CA

7.56M
Shares

$42.4 Million
1.49% of portfolio
Vivo Capital, LLC Palo Alto, CA

6.9M
Shares

$38.6 Million
8.42% of portfolio
Soleus Capital Management, L.P. Greenwich, CT

6.22M
Shares

$34.9 Million
4.41% of portfolio
Deep Track Capital, LP Greenwich, CT

5.58M
Shares

$31.2 Million
1.71% of portfolio
Black Rock Inc. New York, NY

4.12M
Shares

$23.1 Million
0.0% of portfolio

View Full List

About Terns Pharmaceuticals, Inc.

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $211M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

More about TERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Matthews International Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Matthews International Capital Management LLC with notifications on news.

Account